Trial Search Results

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

This pilot clinical trial study will assess the inflammatory response of brain tumors or other central nervous system conditions in pediatric and adult patients using ferumoxytol-enhanced MRI. Imaging features will be correlated with the number of inflammatory cells (macrophages) at histopathology. Determining the extent of inflammation associated with pathologies in the central nervous system may be helpful for diagnostic and prognostic purposes as well as monitoring treatment response of current and future immunotherapies.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Michael Iv

Stanford Investigator(s):

Intervention(s):

  • Drug: Ferumoxytol
  • Other: Tissue Analysis
  • Procedure: Magnetic Resonance Imaging

Phase:

Early Phase 1

Eligibility


Inclusion Criteria:

   - Any patient with suspected brain tumor diagnosed by MRI

   - Patients undergoing neuro-imaging evaluation by the neurosurgical service for other
   indications (e.g. vascular malformations, traumatic brain injury, ischemic and
   hemorrhagic stroke, CNS infections, and neuro-degenerative diseases)

Exclusion Criteria:

   - Informed consent cannot be obtained either from the patient or legal representative

   - Severe coexisting or terminal systemic disease that limits life expectancy or that may
   interfere with the conduct of the study

   - Contraindication to MRI (metal implants)

   - Hemosiderosis/hemochromatosis

   - Need for sedation or anesthesia (claustrophobia) that will not otherwise be undertaken
   as part of routine clinical care (e.g. routine MRI under sedation already planned)

   - Known hypersensitivity to Feraheme (ferumoxytol) or any of its components

   - Iron overload from any cause (not just hemosiderosis or hemochromatosis), even if
   secondary to frequent blood transfusions, severe chronic hemolysis, excess dietary or
   parenteral iron, or any other etiology

Ages Eligible for Study

2 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting